Congratulations to @Argerie Guevara (CBE’23) for taking the thesis option in her undergraduate research and passing it with unanimous consensus today. Her thesis was titled, “PLGA nanoparticles formulations loaded with antibiotics induce sustained and controlled antibiotics release for prolonged antibacterial action against MRSA, and Pseudomonas aeruginosa FRD1,” and is currently being peer-reviewed for publication. Argerie is currently pursuing a PhD in Bioengineering at the Boston University in Boston, MA.
Medical Technology Enterprise Consortium’s (MTEC) 8th Annual Meeting- Richmond, VA (May 23-24, 2023) »
May 01
Argerie Guevara (CBE’23) Successfully Defends her Undergraduate Thesis
Categories:
antibiotics, Antimicrobial, Berthiaume Institute for Precision Health, multidrug resistance, Uncategorized
by Prakash
This post has no tag
Recent Posts
- Phage-Mimicking Antibacterial Nanoparticles Tackle Group A Streptococcal Infections In Vivo January 29, 2024
- 2nd Annual Berthiaume Institute for Precision Health’s Advisory Board Meeting October 30, 2023
- 1st Place Poster at the Military Health Sciences Research Symposium 2023 (Aug 14-17, Kissimmee, FL) August 14, 2023
- Congratulations to Ms. Johanna Olesk on Defending her MS (Bioengineering) ’23 Thesis July 7, 2023
- Translational Science to Impact Public Health was our Goal at Techconnect 2023 June 17, 2023
Archives
Categories
NIH Funding Opportunities
- Notice of Information: Technical Assistance Webinars for PAR-24-206: Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN) (U54 Clinical Trial Optional) May 1, 2024Notice NOT-TR-24-024 from the NIH Guide for Grants and Contracts
- Notice of Intent to Publish a Funding Opportunity Announcement for Addressing Barriers to Healthcare Transitions for Survivors of Childhood and Adolescent Cancers (R01 Clinical Trial Optional) May 1, 2024Notice NOT-CA-24-048 from the NIH Guide for Grants and Contracts
- Notice of Fiscal Policies in Effect for FY 2024 April 30, 2024Notice NOT-OD-24-109 from the NIH Guide for Grants and Contracts
- Notice to Extend PAR-23-101, Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R21 Clinical Trial Optional) April 30, 2024Notice NOT-MH-24-261 from the NIH Guide for Grants and Contracts
- Notice to Extend PAR-23-095, Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) April 30, 2024Notice NOT-MH-24-265 from the NIH Guide for Grants and Contracts
- Notice to Extend PAR-23-093, Utilizing Invasive Recording and Stimulating Opportunities in Humans to Advance Neural Circuitry Understanding of Mental Health Disorders (R01 Clinical Trial Optional) April 30, 2024Notice NOT-MH-24-260 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Promoting Data Reuse for Health Research April 30, 2024Notice NOT-OD-24-096 from the NIH Guide for Grants and Contracts
- Notice of Cancellation of the June 18, 2024 Application Receipt Date for RFA-EY-23-001 "BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)" April 30, 2024Notice NOT-EY-24-005 from the NIH Guide for Grants and Contracts
- Notice of Change to NHGRI-specific language in RFA-HG-23-018, Investigator-Initiated Research in Genomics and Health Equity (R21 Clinical Trial Optional) April 30, 2024Notice NOT-HG-24-032 from the NIH Guide for Grants and Contracts
- Notice of Special Interest (NOSI): Exploring the Effects of Endocannabinoids and Exogenous Cannabinoids on Brain Development April 30, 2024Notice NOT-DA-25-030 from the NIH Guide for Grants and Contracts
Recent Comments